# Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

> **NCT05192304** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Kanion Pharmaceutical Co., Ltd** · enrollment: 62 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** TPN-672

## Key facts

- **NCT ID:** NCT05192304
- **Lead sponsor:** Jiangsu Kanion Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2022-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192304, "Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05192304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*